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Cong-term Outcome of
odgkin Disease Patients
ollowing High-Dose
usulfan, Etoposide,
yclophosphamide, and
utologous Stem Cell
ransplantation—A
imilar Experience
In December 2006, Wadehra et al. [1] reported on
he long-term outcome of Hodgkin’s Disease patients
fter autologous stem cell transplant using a high dose
usulfan, cyclophosphamide, etoposide preparative
egimen. With a median follow-up of 6.7 years, the
-year progression-free survival (PFS) was 48% and
-year overall survival (OS) was 51%. We have had a
imilar experience with essentially the same prepara-
ive regimen at Emory University. Our 5-year OS was
5%, with a median follow-up of 2 years for surviving
atients (see Figure 1).
During the period of 1995 to 2005, we used the
ombination of busulfan, cyclophosphamide, and eto-
igure 1. Kaplan-Meier estimates of survival. Autologous stem cell
ransplant in Hodgkin’s disease using high dose busulfan, cyclo-phosphamide, and etoposide preparative regimen.
46oside as a conditioning regimen for 71 consecutive
atients with Hodgkin’s lymphoma undergoing autol-
gous hematopoietic progenitor cell transplantation.
edian patient age was 32 years (range 19-64 years),
nd 58% of patients were male. The source of pro-
enitor cells was bone marrow for 9 and blood stem
ells for 62 patients (see Table 1). Forty-eight percent
f patients had achieved a complete remission (CR) or
artial remission (PR) at the time of transplant; the
emainder had refractory disease. The median number
f chemotherapy prior to high-dose chemotherapy
as 3.
At our institution, we have administered busulfan
o achieve a total area under the curve (AUC) of
0,000 mol  min/L, integrated over all doses (2-4).
ral busulfan was used between March 1995 and May
004, initiated at a dose of 1 mg/kg by mouth every 6
ours  16 doses. In May 2004 we began using i.v.
usulfan, initiated at 0.9 mg/kg i.v. every 6 hours 16
oses starting on day 8. Sequential busulfan levels
ere obtained with the ﬁrst dose, and the AUC was
alculated using the trapezoidal rule. Busulfan doses
ere adjusted to obtain the targeted levels. Etoposide
as given at a dose of 10 mg/kg/dose every 24 hours
n days 4, 3, and 2, and cyclophosphamide was
iven at a dose of 60 mg/kg every 24 hours on days3
nd 2.
The median number of days to neutrophil engraft-
ent was 12 days, and median time to platelet en-
raftment was 17 days. One hundred-day mortality
ccurred in 2 of 71 patients (3%), because of intracra-
ial hemorrhage in 1 case, and infection in the other
ase. The incidence of veno-occlusive disease (VOD)
sing targeted Bu/Cy/VP16 was low; a concurrent
nalysis of 86 Hodgkin’s and non-Hodgkin’s lym-
homa patients in 2004, who received targeted
usulfan dosing, showed that the incidence of VOD
as only 2.2%. Other regimen-related toxicities
ncluded grade 2-3 mucositis in the majority of
able 1. Patient Characteristics
edian age in years (range) 32 (19-64)
ale vs. female (%) 58% vs. 42%
isease status: CR/PR vs. refractory (%) 48% vs. 52%
tem cell source: bone marrow vs. PBSC (%) 13% vs. 87%
umber of prior chemotherapy regimens
(median) 3
R indicates complete remission; PR, partial remission; PBSC,
peripheral blood stem cell.atients. The recent addition of palifermin admin-
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Letter to the Editor 747stered pre- and postconditioning has helped to re-
uce the incidence of mucositis associated with the
u/Cy/VP16 regimen.
Our institution’s experiences closely parallel the
esults reported by Wadehra et al. and further validate
he toxicity and efﬁcacy proﬁle of this regimen. Post-
ransplant survival was favorable, considering that this
opulation of patients was heavily pretreated, and half
f them had refractory disease at the time of trans-
lant. The low, 3% regimen-related 100-day mortal-
ty observed with this regimen, and the potential for
ccurate patient-speciﬁc targeting of busulfan levels
ffer the possibility that further dose escalation of
usulfan may be possible in the setting of autologous
tem cell transplantation.
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In the article entitled “Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID
Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized by Granulocyte
Colony Stimulating Factor” by Hess et al., in the April 2007 issue of Biology of Blood and Marrow
Transplantation (Volume 13, Number 4, pages 398-411), the third author’s name should have been Timothy
P. Craft (not Timothy C. Craft).
